Pillar_biosciences_logo
  • Investors
  • Careers
  • Investors
  • Careers
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • InheritRevealâ„¢ Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • InheritRevealâ„¢ Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • Inherited Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Careers
  • Investors
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • Inherited Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Careers
  • Investors

Category: Publication

From RUO to Trial-Ready in Six Months Accelerating an FGFR NGS Patient-Selection Assay for a Global Phase 3 Solid Tumor Cancer Trial

CellCarta Case Study
July 2026

Summary Report from the Royal College of Pathologists Forum: Rapid Genomic Testing for Cancer Patients

Publication Source: Royal College of Pathologists

TBC

oncoReveal Methylation Panels, Workflow and performance overview of targeted methylation NGS panels

Publication Source: Pillar Biosciences White Paper

TBC

Targeted NGS as a Frontline Strategy to Accelerate the Precision Treatment of Solid and Heme Tumors

Publication Source: GenomeWeb

TBC

Diagnostics, access, therapies on minds ahead of ASCO

Publication Source: CAP TODAY

TBC

Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers

Publication Source: The Journal of Molecular Diagnostics

TBC

Need for speed in solid tumor molecular testing

Publication Source: CAP TODAY

TBC

Minimizing Sample Failure Rates for Challenging Clinical Tumor Samples

Publication Source: The Journal of Molecular Diagnostics

TBC

Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?

Publication Source: American Society of Clinical Oncology

TBC

Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology

Publication Source: Journal of Clinical Pathology

TBC

Next →
Pillar_biosciences_logo
Map-marker-alt Linkedin-in
Privacy Policy
© 2026 Pillar Biosciences. All rights reserved.